Nathan Boggs MD, Ph.D.

Education

Allergy & Immunology Fellowship, National Institute of Allergy and Infectious Diseases (2019)
Internal Medicine Residency, Yale-New Haven Hospital (2017)
MD Uniformed Services University (2014)
Ph.D. Plant Molecular Biology, Cornell University (2009)
B.S. Plant & Soil Science, University of Vermont (2003)

Biography

Dr. Nathan Boggs developed an international clinical registry for Tricare beneficiaries known, or suspected to have, the myeloid neoplasm systemic mastocytosis. The registry is designed to reduce the time to diagnosis and improve the care of those who are diagnosed. Dr. Boggs has developed clinical and research collaborations with ARUP labs and the National Institutes of Health (NIH) Clinical Center and helped Walter Reed obtain a Center of Excellence designation by the American Initiative in Mast Cell Diseases (AIM).

Dr. Boggs is principal investigator (PI) of multiple prospective research studies. One study, in collaboration with Drs. Clifton Dalgard and Andrew Snow at USU, aims to improve genetic diagnosis rates compared to standard of care for patients with inborn errors of immunity and mastocytosis. The study utilizes a whole genome and RNA sequencing approach. A second study is assessing the genetic underpinning of urticaria.

Dr. Boggs is the Walter Reed site PI for three clinical trials geared towards helping patients with systemic mastocytosis.
https://clinicaltrials.gov/study/NCT05186753
https://clinicaltrials.gov/study/NCT06915766
https://clinicaltrials.gov/study/NCT04655118

See the following link for more information on the American Initiative in Mast Cell Diseases Centers of Excellence.
https://aimcd.net/centers/

Representative Bibliography

Schornack BJ, McMurray JC, Leondaridis M et al. Well-differentiated systemic mastocytosis: Genetics, mast cell immunophenotypes, and KIT autophosphorylation. JACI. 2025.

McMurray JC, Schornack BJ, Adams KE et al. Fire ant-venom anaphylaxis prevalence in the general population and patients with systemic mastocytosis. Frontiers in Allergy. 2025.

Ezekwe EAD Jr, Weskamp AL et al. Dupilumab Use in Patients With Hypereosinophilic Syndromes: A Multicenter Case Series and Review of the Literature. JACI-In Practice. 2024.

McMurray JC, Pacheco CS, Schornack BJ et al. Standardized indolent systemic mastocytosis evaluations across a healthcare system: implications for screening accuracy. Blood. 2024.

Soderstrom MA, Miller MA, Wang Q et al. Vaccine utilization and overwhelming post-splenectomy infection risk factors in two asplenia cohorts. Haematologica. 2023

Boggs NA, Sun X, Lyons JJ et al. Challenges in Applying Diagnostic Criteria for Systemic Mastocytosis. Blood Advances. 2023

Waters AM, Park HJ, Weskamp AL et al. Elevated Basal Serum Tryptase: Disease Distribution and Variability in a Regional Health System. JACI-In Practice. 2022.

Boggs NA and Rao VK. The role of bone marrow evaluation in clinical allergy and immunology practice: When and why? JACI-In Practice. 2020.